Britain and America have reached a landmark trade agreement that will guarantee no duties on UK medicine shipments being sold in the American market.
Agreement Details of the Deal
In exchange for the tariff guarantee, the UK has committed to boost expenditure on medicines through the NHS. This move guarantees that duties on these key goods will remain at nothing for a duration of 36 months.
This deal follows recent warnings to dramatically increase import taxes on branded pharmaceutical imports, with potential rates discussed as high as double the cost.
"This agreement with the United Kingdom strengthens the global environment for new treatments and brings much-needed fairness to American-British pharmaceutical trade," a release said.
Trade Impact
Pharmaceuticals are one of the the United Kingdom's biggest exports to the US, which is by far the primary market for large UK drugmakers.
Statistics indicate that in the year prior to last September, the UK sold drugs worth billions to the US. This figure represented a significant portion of total UK exports in that period.
"This guarantee safeguards employment, stimulates investment and sets the stage for the UK to emerge as a international leader for biotech and pharma," a minister commented.
Detailed NHS Changes
The pact involves several notable commitments from the UK:
- Revised Affordability Limit: The UK will lift the affordability limit at which it deems new medicines to be unaffordable by a quarter.
- Increased NHS Spending: There is a target to double overall public funding on treatments from 0.3 percent of the national economy to 0.6 percent over the following ten-year period.
- Refund Ceiling: The percentage drug companies must refund to the NHS to control costs will be limited at 15%. Last year, refunds exceeded 20%.
Industry Background
The deal follows a protracted row between the sector and the ministers over medicine costs and regulatory access.
This friction were intensified by claims that American patients were paying several times more for the same drugs than patients in the Britain and the EU.
In recent months, several significant pharmaceutical investments in the UK have been delayed or abandoned, while major funding commitments have been directed toward American operations.
The Science Minister stated that the NHS had to invest a greater share on drugs, noting that its spending on drugs had declined as a proportion of its total funding over the past decade.
